BIO.News Newsletter

Today, we take a deep dive into what’s been happening in the state legislatures—here’s what BIO’s watching related to healthcare and agriculture. Plus, two bills designed to strengthen U.S. patents were introduced May 1. (790 words, 3 minutes, 57 seconds)

BIO launches a new campaign to explain why we vaccinate – and why it's good for America. We have details, plus how drug companies are investing in U.S. manufacturing, news on drug prices and IP, and more. (740 words, 3 minutes, 42 seconds)

A busy April is flying by. Today, we look at the executive order on drug pricing, the threat of pharmaceutical tariffs, a CDC meeting on immunization practices, and BIO’s appearances at many conferences across the U.S. (750 words, 3 minutes, 45 seconds)

Today, we have details on the National Security Commission on Emerging Biotechnology’s new report—and why tariffs still threaten biotech, including pharma and ag. (816 words, 4 minutes, 4 seconds)

A busy week brings discussions on tariffs, PBMs, and many hearings ahead. (896 words, 4 minutes, 28 seconds)

Another busy week begins with BIO’s new survey of member views on tariffs and a BIO Board member’s congressional testimony on how legislation can help small biotechs. (747 words, 3 minutes, 44 seconds)

A new report released by BIO highlights the potential of the bioeconomy – if we give it support. Plus, more news on federal funding for bird flu interventions, the need to invest in women's health, and more. (691 words, 3 minutes, 27 seconds)

Patient advocates explain why the Pediatric Priority Review Voucher (PPRV) Program must be reauthorized, and National Ag Day highlights the links between biotech and agriculture. (982 words, 4 minutes, 52 seconds)P.S. If you’re in D.C., BIO is sponsoring today’s AgriPulse 2025 Ag & Food Policy Summit, "Navigating Taxes, Trade and Technology: What's Ahead for Food & Agriculture." BIO members BASF and Pivot Bio will also speak.

BIO President & CEO John F. Crowley writes Congress to urge PPRV passage; plus a deep dive into the impact of autoimmune disease on women. (761 words, 3 minutes, 48 seconds)

A busy week in Washington, D.C., brought legislation to fix the Inflation Reduction Act “pill penalty,” bipartisan calls for PBM reform, and BIO CEO John F. Crowley explaining why Congress needs to act to support rare disease drug development. (1012 words, 5 minutes, 3 seconds)